AIHTA - Publications - Search - Items where Subject is "WI 400-560 Intestines"
Number of items at this level: 52.

Adlbrecht, C. and Breyer, E. and Gartlehner, G. and Guba, B. (2008): Selective Cell Apheresis in Inflammatory Bowel Disease. Decision Support Document 11.

Adlbrecht, C. and Warmuth, M. (2012): Radiofrequency ablation of primary tumours of the gastrointestinal tract (colorectal and pancreatic cancer). Decision Support Document 58.

Adlbrecht, C. and Wild, C. (2010): Radionuclide therapy - 90Yttrium and 177Lutetium somatostatin analogues for the treatment of inoperable neuroendocrine tumors. Decision Support Document 40.

Adlbrecht, C. and Wild, C. (2007): [Targeted radionuclide therapy with 90Y- and 177-Lu-DOTATOC in patients with neuroendocrine tumors. HTA in hospitals]. Decision Support Document 02.

Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Fischer, S. and Zechmeister, I. (2011): Sacral Nerve Stimulation for Fecal Incontinence. Rapid Assessment 004.

Fischer, S. and Zechmeister-Koss, I (2012): Day Surgery. HTA- Projektbericht 64.

Fischer, S. and Zechmeister-Koss, I. and Huic, M. (2013): Duodeno-jejunal bypass liner (DJBL) for patients with obesity, with/without type 2 diabetes mellitus . Decision Support Document 67.

Goetz, G. (2021): Stool DNA testing for colorectal cancer (CRC) screening. AIHTA Policy Brief 011.

Grössmann, N. (2021): Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI-H or dMMR colorectal cancer. Update April 2021. Oncology Fact Sheet Nr. 34.

Grössmann, N. (2020): Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Update July 2020. Oncology Fact Sheet Nr. 7.

Grössmann, N. (2017): Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC). DSD: Horizon Scanning in Oncology 75.

Hintringer, K. (2011): Panitumumab (Vectibix®) as 1st-line combination therapy for the treatment of WT KRAS metastatic colorectal cancer - 1st Update 2011. DSD: Horizon Scanning in Oncology 11 / Update 2011.

Hintringer, K. (2010): Panitumumab (Vectibix ®) for the first-line treatment of metastatic colorectal cancer. DSD: Horizon Scanning in Oncology 11.

Hintringer, K. and Wild, C. (2009): Colon Hydrotherapy for defecation disorders. Systematic Review. Decision Support Document 32.

Jonas, S. and Rafetseder, O. and Wild, C. (2003): [Colorectal cancer screening in Austria: Integrating coloscopy/sigmoidoscopy into the preventive medical check up. An unsystematic review]. ITA-Projektbericht 25.

Jonas, S. and Schamberger, C. and Wild, C. (2002): [Predictive genetic diagnosis for breast and colon carcinoma: Diagnosis, treatment, public health aspects]. ITA-Projektbericht 21.

Jonas, S. and Rafetseder, O. and Wild, C. (2005): [Colorectal cancer screening in Austria: Integrating coloscopy into the preventive medical check up]. Journal für Gastroenterologische und hepatologische Erkrankungen 03: pp. 11-15.

Jonas, S. and Wild, C. and Schamberger, C. (2003): [Predictive genetic testing for breast and colorectal cancer]. ZaeFQ: Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 97 (01): pp. 67-71.

Jonas, S. and Wild, C. and Schamberger, C. (2002): Predictive genetic testing for mammary and colorectal cancer. Wiener Klinische Wochenschrift 114 Suppl. (17-18): p. 24.

Kisser, A. and Kirisits, A. (2014): Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of peritoneal carcinomatosis . Decision Support Document 74.

Nagele, M. (2006): [Computed tomographic colonography (CTC) for colon cancer screening]. HTA-Newsletter 51: p. 4.

Patera, N. (2013): Screening for Colorectal Cancer. Part 3: Status of screening-activities and quality assurance of screening-colonoscopy. HTA-Projektbericht 41c.

Patera, N. (2010): Screening for Colorectal Cancer. Part 1: Screening-Tests and Project Design. (2nd revised edition). HTA-Projektbericht 41a.

Patera, N. and Schumacher, I. (2012): Screening for Colorectal Cancer. Part 1: Screening Tests and Program Design (3. updated edition). HTA-Projektbericht 41a.

Patera, N. and Schumacher, I. (2012): Screening for Colorectal Cancer. Part 2: Health economic evaluations and cost dynamics (2. updated edition). HTA-Projektbericht 41b.

Puig, S. and Staudenherz, A. and Felder-Puig, R. and Paya, K. (2008): Imaging of appendicitis in children and adolescents: Useful or useless? A comparison of imaging techniques and a critical review of the current literature. Seminars in Roentgenology 43 (1): pp. 22-28.

Radlberger, P. and Zechmeister, I. (2010): Screening for Colorectal Cancer. Part 2: Health economic evaluations and developments of costs. HTA-Projektbericht 41b.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the treatment of microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic colorectal cancer, advanced or recurrent endometrial carcinoma and unresectable or metastatic gastric, small intestine, or biliary cancer. Update July 2022. Oncology Fact Sheet Nr. 90.

Rothschedl, E. and Wolf, S. (2021): Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST). Update May 2022. Oncology Fact Sheet Nr. 62.

Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Update September 2022. Oncology Fact Sheet Nr. 16.

Rothschedl, E. and Nachtnebel, A. (2014): Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma. DSD: Horizon Scanning in Oncology 46.

Rothschedl, E. and Nachtnebel, A. (2013): Regorafenib (Stivarga®) for heavily pretreated patients with metastatic colorectal cancer (mCRC). DSD: Horizon Scanning in Oncology 40.

Rothschedl, E. and Nachtnebel, A. (2013): Aflibercept (Zaltrap®) in addition to FOLFIRI for the 2nd line therapy of metastatic colorectal cancer. DSD: Horizon Scanning in Oncology 38.

Schmidt , L. and Lohr, P. and Prenner, A. and Poerio, E. and Ceresola, E. and Andretta, M. and Cavazzana, A. (2019): Robot-assisted surgery in thoracic and visceral indications. HTA-Projektbericht 108.

Wild, C. (2006): [Infliximab for Crohn’s disease]. HTA-Newsletter 45: p. 2.

Wild, C. (2005): [Targeted therapies]. ITA-Newsletter September 2005: pp. 11-12.

Wild, C. (2005): [Avastin®/Bevacizumab for metastatic colorectal cancer]. HTA-Newsletter 40: p. 2.

Wild, C. (2005): [Erbitux®/Cetuximab for metastatic colorectal cancer]. HTA-Newsletter 40: pp. 2-3.

Wild, C. (2004): [Screening for colorectal cancer in Austria]. HTA-Newsletter 25: pp. 2-3.

Wild, C. (2003): [The digestive endoscopic imaging capsule]. HTA-Newsletter 20: pp. 2-3.

Wild, C. (2003): [Virtual colonoscopy]. HTA-Newsletter 18: pp. 2-3.

Wild, C. (2002): [Infliximab for Crohn's disease]. HTA-Newsletter 11: p. 4.

Wild, C. (2002): [Predictive genetic testing for breast and prostate cancer]. HTA-Newsletter 07: p. 2.

Wild, C. (2002): [Screening for colorectal cancer]. HTA-Newsletter 04: p. 4.

Wild, C. and Adlbrecht, C. (2007): [Radiopharmaceuticals in palliative care]. HTA-Newsletter 58: pp. 2-3.

Wild, C. (2005): [Avastin®/Bevacizumab for metastatic colorectal cancer]. ÖKZ: Österreichische Krankenhauszeitung 46 (10): p. 51.

Wild, C. and Jonas, S. (2002): [Predictive genetic testing for breast and colon cancer]. Newsletter der Österreichischen Gesellschaft für Public Health (3): p. 1.

Wild, C. and Jonas, S. and Rafetseder, O. (2004): [Colon cancer screening]. Mitteilungen der Sanitätsverwaltung 11: pp. 14-15.

Wolf, S. (2022): Tegafur/gimeracil/oteracil (Teysuno®) for the treatment of metastatic colorectal cancer. Update March 2022. Oncology Fact Sheet Nr. 76.

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer. Update September 2021. Oncology Fact Sheet Nr. 51.

Wolf, S. and Stanak, M. (2018): Allogeneic mesenchymal stem cells for Crohn’s disease-associated complex perianal fistulas. Decision Support Document 111.

This list was generated on Sun Oct 2 01:00:23 2022 CEST.